Document is current
Any future updates will be listed below
-
Authors
Giordano, Giorgia
Tucciarello, Cristina
Gucciardo, Erika
Wesche, Jørgen
Meza-Zepeda, Leonardo A.
Myklebost, Ola
Tirtei, Elisa
Merlini, Alessandra
Comparato, Simona
Cutrupi, Santina
D’Ambrosio, Lorenzo
Fagioli, Franca
Sangiolo, Dario
Isella, Claudio
Sapino, Anna
Marchiò, Caterina
Grignani, Giovanni
Pignochino, Ymera
-
Funding
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (31439-2024)
Fondazione AIRC per la ricerca sul cancro ETS (IG 20259)
Fondazione AIRC per la ricerca sul cancro ETS (IG 23104)
Norges Forskningsråd (262652)
Barnekreftforeningen (144385)
Fondazione Piemontese per la Ricerca sul Cancro (FPRC) Onlus (5x1000 MUR 2023-IMCURE project)
Fondazione Piemontese per la Ricerca sul Cancro (FPRC) Onlus (MUR 2020 K9-HUMAN PROGRAM)
EdiREX (EuroPDX transnational access)
Ministero della Salute (GR-2016-02362726)
- License Information
-
More Information
Article History
Received: 12 March 2026
Accepted: 17 July 2026
First Online: 3 September 2026
Declarations
Ethics approval and consent to participate: All participants provided written informed consent in accordance with a protocol that adheres to the Declaration of Helsinki, and the study was approved by the local Institutional Review Board and Ethics Committee (approval number 296–2020/14-OCT-2020), or the Committee for Medical Ethics of South-Eastern Norway (approval 17866). Animal study was approved by the Institutional Animal Welfare Organization (OPBA) of the Candiolo Cancer Institute and by the Italian Ministry of Health (Prot. 21635.18, Aut. Min. 834/2019-PR).
Consent for publication: Not applicable.
Competing interests: AM: PharmaMar, support for meeting participation and Institutional Grant; GGr: fees for consulting and advisory board roles from PharmaMar, Lilly, Novartis, GSK, Bayer, and Eisai. LDA: PSI CRO Italy, GSK, AstraZeneca, Eisai, and Boehringer Ingelheim, Advisory Board; support for meeting participation from PharmaMar and AstraZeneca.
